InvestorsHub Logo
Followers 3
Posts 292
Boards Moderated 0
Alias Born 12/21/2022

Re: None

Monday, 02/06/2023 6:46:35 PM

Monday, February 06, 2023 6:46:35 PM

Post# of 3283
Rolvedon sales estimate from Hanmi.
By Jae-Young Han Feb 02, 2023
Launched in the US last October, the drug is expected to account for 2% of the country's neutropenia treatment market in 2023.
Rolvedon is expected to post about $60 million in revenue in the US market this year, accounting for 2% of neutropenia treatment in the country.
https://www.kedglobal.com/bio-pharma/newsView/ked202302020001